Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Background: At present, controversy remains regarding whether cytoreductive prostatectomy (CRP) should be performed for oligometastatic prostate cancer (OPC). The purpose of this study was to assess the efficacy of CRP for the treatment of OPC by conducting a systematic meta-analysis . Methods: : Design A systematic review and meta-analysis, conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.Data sources Publications included in the PubMed, Embase, the Cochrane Library, EBSCO, Web of Science (SCI) databases as of May 2022.Eligibility criteria Prospective studies comparing the efficacy of RP versus no RP in the treatment of OPC. Results: : In total, 11 publications incorporating 888 patients were analyzed. Tumor-reducing prostatectomy was found to have no significant effect on long-term or short-term OS [OR=2.26, 95%CI(0.97,5.28), P=0.06 > 0.05] and [OR=1.73, 95%CI(0.83,3.58), P=0.14 > 0.05], but it significantly improved patient CSS [OR=1.77, 95%CI(1.01,310.), P=0.04 < 0.05]and[OR=2.71, 95%CI(1.72,4.29), P < 0.0001] and PFS [OR=1.93, 95%CI (1.25, 2.97), P=0.003 < 0.05]. Conclusion: These results suggest that cytoreductive prostatectomy can confer survival benefits to OPC patients.